INCIDENCE AND RISK FACTORS FOR ORAL MUCOSITIS AFTER BONE MARROW TRANSPLANTATION PATIENTS UNDER LOW INTENSITY LASER THERAPY: A LONGITUDINAL STUDY

Authors

  • Cassia Emanuella Nobrega Malta Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil
  • Maria Imaculada de Queiroz Rodrigues Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil
  • José Vitor de Mota Lemos Post-graduate program in Dental Sciences, Unichristus, Fortaleza, Brazil
  • Natalia Costa Bezerra Freire Nurse Coordinator of the Bone Marrow Transplant Unit at the University Hospital Walter Cantídio (HUWC)
  • Fernando Barroso Duarte Postdoctoral fellow at the Fred Hutchinson Cancer Research Center (Fred Hutch), Head of the Hematology, Clinical Oncology and Bone Marrow Transplant Department at the Hospital Universitário Walter Cantídio/EBSERH /UFC, responsible for the implantation of the bone marrow transplant in Ceará, Member of the editorial board of the Latin American Bone Marrow Transplantation
  • Paulo Goberlânio de Barros Silva Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil
  • Ana Paula Negreiros Nunes Alves Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil

DOI:

https://doi.org/10.46765/2675-374X.2020v2n1p44-54

Keywords:

Hematopoietic Stem Cell Transplantation; Mucositis; Low Intensity Light Therapy

Abstract

Bone marrow transplantation (BMT) has been used to treat numerous malignant and non-malignant hematological diseases, genetic and immunological diseases with a high risk of oral mucositis (OM) due to the action of antineoplastic drugs. As photobiomodulation therapy (FBMT) with low-level laser is a proven non-invasive treatment for OM, the objective of this study was to evaluate the incidence of OM in patients on BMT undergoing FBM. 53 patients undergoing treatment received FBMT (red laser, 2J, 20s, 100mW) as a preventive protocol. If MO was observed, an infrared laser (4J, 40s, 100W) was administered. The following data were collected from patients' medical records: sex, age, chemotherapy protocol (QT) and type of BMT. An incidence of 34% was observed in the population studied (20% grade I, 11.3% grade II and 1.9% grade III). Prevention protocols using FBMT significantly reduced the incidence of oral mucositis (p = 0.004). Now, young patients with myeloid leukemia, the time between QT and BMT (p = 0.010) and time of QT (p = 0.018) were directly associated with the increased incidence of oral mucositis. It was concluded that low-intensity preventive laser therapy was associated with a reduction in the incidence of oral mucositis, showing the importance of this therapy in the management of patients undergoing BMT.

Downloads

Published

10/14/2020

How to Cite

Malta, C. E. N., Rodrigues, M. I. de Q., Lemos, J. V. de M., Freire, N. C. B., Duarte, F. B., Silva, P. G. de B., & Alves, A. P. N. N. (2020). INCIDENCE AND RISK FACTORS FOR ORAL MUCOSITIS AFTER BONE MARROW TRANSPLANTATION PATIENTS UNDER LOW INTENSITY LASER THERAPY: A LONGITUDINAL STUDY. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(3), 44–54. https://doi.org/10.46765/2675-374X.2020v2n1p44-54

Issue

Vol. 1 No. 3 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)

1 2 3 > >>